Objective: We decided to investigate the role of this polymorphism on cardiovascular risk factors and weight loss secondary to a high-protein/low-carbohydrate vs. a standard hypocaloric diet (1,000 kcal/day) over a period of 9 months. Material and methods: A nutritional evaluation was performed at the beginning and at the end of a 9-month period in which subjects received 1 of 2 diets (diet HP: high protein/low carbohydrate vs. S: standard diet). Results: One hundred and four patients (54.7%) had the genotype G1359G and 86 (45.3%) patients had G1359A (77 patients, 25.8%) or A1359A (9 patients, 3.7%) (A-allele-carriers). In subjects with both genotypes, the body mass index, weight, fat mass, waist circumference and systolic blood pressures decreased with both diets. After the diet type HP and in subjects with both genotypes, the glucose, leptin, total cholesterol, LDL-cholesterol, insulin and HOMA-R levels decreased. After diet S and in all subjects, the total cholesterol, LDL cholesterol and leptin levels decreased, too. Conclusion: Our interventional study didn't show a relationship between the rs1049353 CNR-1 polymorphism and body weight response after two different hypocaloric (low carbohydrate/high protein vs. standard) diets over a period of 9 months. However, a low-carbohydrate/high-protein diet for 9 months improved glucose metabolism in subjects with both genotypes.

Keywords:
Cannabinoid receptor gene, High protein/low carbohydrate, Standard hypocaloric diet, Obesity, Weight
1.
Hu T, Mills KT, Yao L, et al: Effects of low-carbohydrate diets versus low-fat diets on metabolic risk factors: a meta-analysis of randomized controlled clinical trials. Am J Epidemiol 2012;176(suppl 7):S44-S54.
2.
Castañeda-González LM, Bacardí Gascón M, Jiménez Cruz A: Effects of low carbohydrate diets on weight and glycemic control among type 2 diabetes individuals: a systemic review of RCT greater than 12 weeks. Nutr Hosp 2011;26:1270-1276.
3.
Nordmann AJ, Nordmann A, Briel M, et al: Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch Intern Med 2006;166:285-293.
4.
Bueno NB, de Melo IS, de Oliveira SL, et al: Very-low-carbohydrate ketogenic diet v. low-fat diet for long-term weight loss: a meta-analysis of randomised controlled trials. Br J Nutr 2013;110:1178-1187.
5.
Nordmann AJ, Suter-Zimmermann K, Bucher HC, et al: Meta-analysis comparing Mediterranean to low-fat diets for modification of cardiovascular risk factors. Am J Med 2011;124:841-851.e2.
6.
Ameri A: The effects of cannabinoids on the brain. Prog Neurobiol 1999;58:315-348.
7.
Felder CC, Glass M: Cannabinoid receptors and their endogenous agonists. Annu Rev Pharmacol Toxicol 1998;38:179-200.
8.
de Luis DA, González Sagrado M, Aller R, Izaola O, Conde R: Influence of G1359A polymorphism of the cannabinoid receptor gene on anthropometric parameters and insulin resistance in women with obesity. Metabolism 2011;60:272-276.
9.
Luis DA, González Sagrado M, Aller R, Izaola O, Conde R, Pérez Castrillón JL, Romero E: [G1359A polymorphism of the cannabinoid receptor gene (CNR1) on anthropometric parameters and cardiovascular risk factors in patients with morbid obesity]. Nutr Hosp 2009;24:688-692.
10.
de Luis DA, González Sagrado M, Aller R, Izaola O, Conde R, Pérez Castrillón JL, Romero E: G1359A polymorphism of the cannabinoid receptor gene (CNR1) and insulin resistance in patients with diabetes mellitus type 2. Nutr Hosp 2010;25:34-38.
11.
Aberle J, Fedderwitz I, Klages N, George E, Beil FU: Genetic variation in two proteins of the endocannabinoid system and their influence on body mass index and metabolism under low fat diet. Horm Metab Res 2007;39:395-397.
12.
de Luis DA, González Sagrado M, Aller R, Conde R, Izaola O, de la Fuente B, Primo D: Roles of G1359A polymorphism of the cannabinoid receptor gene (CNR1) on weight loss and adipocytokines after a hypocaloric diet. Nutr Hosp 2011;26:317-322.
13.
Antonio de Luis D, Sagrado MG, Aller R, Izaola O, Conde R, De la Fuente B: Role of G1359A polymorphism of the cannabinoid receptor gene on weight loss and adipocytokines levels after two hypocaloric diets. J Nutr Biochem 2012;23:287-291.
14.
de Luis DA, Aller R, Gonzalez Sagrado M, Conde R, Izaola O, de la Fuente B: Genetic variation in the cannabinoid receptor gene (CNR1) (G1359A polymorphism) and their influence on anthropometric parameters and metabolic parameters under a high monounsaturated vs. high polyunsaturated fat hypocaloric diets. J Nutr Biochem 2013;24:1431-1435.
15.
Mataix J, Mañas M: Tablas de composición de alimentos españoles. University of Granada, 2003.
16.
Duart Duart MJ, Arroyo CO, Moreno Frígols JL: Validation of a kinetic model for the reactions in RIA. Clin Chem Lab Med 2002;40:1161-1167.
17.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-414.
18.
Lehmann HP, Block D, Markert-Hahn C, Zolg JW: New concepts in systemic autoimmunity testing. Scand J Clin Lab Invest Suppl 2001;235:84-90.
19.
Lukaski HC, Johnson PE: Assessment of fat-free mass using bioelectrical impedance measurements of the human body. Am J Clin Nutr 1985;41:810-817.
20.
Gazzerro P, Caruso MG, Notarnicola M, Misciagna G, Guerra V, Laezza C, Bifulco M: Association between cannabinoid type-1 receptor polymorphism and body mass index in a southern Italian population. Int J Obes (Lond) 2007;31:908-912.
21.
Aberle J, Flitsch J, Beck NA, Mann O, Busch P, Peitsmeier P, Beil FU: Genetic variation may influence obesity only under conditions of diet: analysis of three candidate genes. Mol Genet Metab 2008;95:188-191.
22.
Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G: Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001;410:822-825.
23.
Cota D, Marsicano G, Tschöp M, Grübler Y, et al: The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003;112:423-431.
24.
Liu YL, Connoley IP, Wilson CA, Stock MJ: Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes (Lond) 2005;29:183-187.
25.
de Luis DA, González Sagrado M, Aller R, Izaola O, Conde R: Relation of G1359A polymorphism of the cannabinoid receptor (CB1) gene with metabolic syndrome by ATP III classification. Diabetes Metab Res Rev 2011;27:506-511.
26.
de Luis DA, Pacheco D, Aller R, Gonzalez Sagrado M, Conde R, Izaola O, Cuellar L, Terroba MC, Martin T, Ventosa M: G1359A polymorphism of the cannabinoid receptor gene (CNR1) and clinical results of biliopancreatic diversion. Eur Rev Med Pharmacol Sci 2010;14:197-201.
27.
Santos FL, Esteves SS, da Costa Pereira A, et al: Systematic review and meta-analysis of clinical trials of the effects of low carbohydrate diets on cardiovascular risk factors. Obes Rev 2012;13:1048-1066.
28.
Kodama S, Saito K, Tanaka S, et al: Influence of fat and carbohydrate proportions on the metabolic profile in patients with type 2 diabetes: a meta-analysis. Diabetes Care 2009;32:959-965.
29.
de Luis DA, Ovalle HF, Soto GD, Izaola O, de la Fuente B, Romero E: Role of genetic variation in the cannabinoid receptor gene (CNR1) (G1359A polymorphism) on weight loss and cardiovascular risk factors after liraglutide treatment in obese patients with diabetes mellitus type 2. J Investig Med 2014;62:324-327.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.